There's a familiar pattern in digital health: raise venture money, sign up doctors, promise convenience. Then comes the hard part—convincing people to actually use it.
DrHouse, a 24/7 telemedicine platform launched in New York by Estonian co-founders Ergo Sooru and Sten Tarro, thinks it has found an edge. The company closed a $3.5 million seed round between late May and early July 2024—sources familiar with the deal place it between late May and early July—from Specialist VC, Trind Ventures, and a handful of U.S. angels. But the money itself wasn't the story. What followed was.
In the year and a half since that capital hit the bank, DrHouse has methodically assembled something resembling actual infrastructure: major insurance partnerships, thousands of lab testing sites, and most notably, same-day prescription delivery in select cities. Whether that's enough to stand out in a crowded field remains an open question.
The Delivery Gambit
Virtual care has a last-mile problem, and it's literal. A patient finishes a video consultation—say, for a urinary tract infection or a migraine—only to face the same old friction: drive to a pharmacy or wait days for mail order. DrHouse is wagering that bundling one-hour delivery with the consult itself removes enough hassle to matter.
The rollout started small. New York City in February 2025. Then Florida statewide that August, marketed as the first end-to-end telehealth app in the state to offer complimentary one-hour delivery. Dallas–Fort Worth followed in December. The company isn't blanketing the country overnight, but the geographic expansion suggests deliberate testing of logistics and unit economics in different markets.
Sooru and Tarro, who founded the company in 2021, have kept the pricing straightforward: $129 per visit for self-pay patients, consultation and prescription included. Employer groups of 10 to 100 can opt in at $9 per employee monthly. Board-certified clinicians are available around the clock in all 50 states, the company says, though the actual panel likely relies heavily on contract physicians—standard practice for platforms at this stage.
Building the Insurance Footprint
DrHouse spent much of 2024 and 2025 adding major payers. Aetna, UnitedHealthcare, Blue Cross Blue Shield, and Medicare came aboard in August 2024, according to Baltic VC, which first reported the seed raise in June 2024. Elevance Health joined in February 2025; Humana, that July. The Labcorp partnership, struck in October 2024, gave users access to more than 6,000 lab testing sites nationwide—useful for conditions that require follow-up bloodwork.
Trind Ventures, an early-stage fund that had previously backed DrHouse in 2022, returned for the seed round. Specialist VC, a Baltic firm investing across the Baltics, Finland, and Ukraine with a €50 million fund, also participated. The funding was earmarked largely for marketing, per Baltic VC's reporting at the time.
The insurance additions matter. Reimbursement pathways remain open—Congress extended Medicare telehealth flexibilities through the end of 2027 in a February 2026 vote—but consumer adoption in virtual care often hinges on whether a service is in-network. DrHouse now has that box checked, at least with the major national carriers.
The Competitive Reality
As of early March, DrHouse claimed 100,000 signups on LinkedIn. That figure is self-reported and hasn't been verified by third parties, so treat it with the usual caution. Public records suggest the team sits somewhere between 51 and 200 employees, a range typical of early-stage digital health companies that lean on contract clinical networks rather than full-time staff.
The broader market remains crowded and noisy. Teladoc, Included Health, Hims & Hers—all continue to scale aggressively, validating the category but also raising the bar for what it takes to break through. Prescription delivery alone won't guarantee differentiation; Amazon Pharmacy and others already offer speed on fulfillment. The question is whether DrHouse can make the entire experience—diagnosis to delivery—seamless enough that patients choose it over established competitors.
What Happens Next
The company now sits at something of an inflection point. Infrastructure: in place. Payers: on board. Fulfillment: expanding, if still geographically limited. The obvious next step is proving the model works at scale, which will require converting signups into repeat users and demonstrating that the delivery advantage translates into sustainable growth.
That will determine whether DrHouse can command the terms it wants in a Series A—or whether investors will push back on burn rates and customer acquisition costs, as they have across much of digital health lately. Sooru and Tarro have built a platform that addresses real friction in telemedicine. Now comes the less glamorous work of making the numbers pencil out.
